2
Onco - Neuro Prime TM All Rights Reserved | Saarum Sciences Pvt. Ltd., 1st Floor, AIMSR Building, Apollo Health City, Jubilee Hills, Hyderabad 500096, India | http://www.saarum.com SAARUM SCIENCES Phenotypic Platforms for Drug & Biomarker Discovery Figure 3. High grade glioma cells were cultured in serum free media on non-adherent plates for 10 to 15 days to form three dimensional growth known as Neurospheres. These 3D Neurospheres are true in vitro representation of human brain tumors and can be used for drug screening and imaging based studies. For comparison, Neurospheres generated from U87MG cell line is shown in the right panel. Bendamusne Concentraon 0 0.1 0.2 0.3 0.4 0.5 DMSO IC25 IC75 Absorbance at 450 nm Bendamustine cells + DMSO 0.8 um 4 uM 20 uM 100 uM 500 uM 0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 m n 0 5 4 t a e c n a b r o s b A 0.00 0.50 1.00 1.50 2.00 2.50 3.00 3.50 4.00 Onco Prime TM Use a primary cell-based platform that truly represents the clinical diversity of brain cancer - Switch to “ Patient cells characterized across several passages “ Why use 2D cell lines when you can take advantage of 3D primary cell cultures “ Onco Prime TM platform is ideally suited for drug screening & lead optimization “ U87MG - IC25/IC75 Titration Cells + 0.225% DMSO IC 25 IC 75 1000 cells 2500 cells 5000 cells P1, Day 4 P1, Day 12 P2, Day 4 P2, Day 12 U87MG cell line, Day 10 U87MG cell line, Day 15 High grade glioma, Day 10 High grade glioma, Day 15 10X 10X 10X 10X Figure 4. Effect of reference compounds. Cytotoxicity assay on neurospheres treated with Bendamustine at doses IC 25 and IC 75 Figure 2. Cells derived from patient tumours proliferate well in primary cultures and maintain their morphology through successive generations. Representative phase contrast images of High grade glioma. Images acquired at 100X mag. Figure 1b. Diversity of samples available in our biobank. With steady inflow of patient samples, we have banked a generous diversity of Breast cancer samples. The chart represents high level categories only. Brain cancer subtypes as defined by WHO criteria. Figure 1a. Glioma classification based on lineage. Schematic representation of the differentiation process of neural stem cells into different cell lineages of the CNS and putative cells of origin of gliomas. WHO grading is shown in table. ASTROCYTOMA OF BRAIN ADENOCARCINOMA, METASTATIC, NOS LOW-GRADE FIBROMYXOID SARCOMA GLIOBLASTOMA MULTIFORME OF BRAIN NON-HODGKIN'S LYMPHOMA GLIOBLASTOMA NOS PITUITARY ADENOMA MENINGIOMA NOS NEOPLASM OF BRAIN GANGLIOGLIOMA GEMISTOCYTIC ASTROCYTOMA CEREBRAL ARTERIOVENOUS MALFORMATION TRIGEMINAL SCHWANNOMA TUBERCULOSIS PRIMITIVE NEUROECTODERMAL TUMOR TRICHILEMMAL CYST EPIDERMOID CYST OLIGODENDROGLIOMA, ANAPLASTIC MENINGOTHELIAL MENINGIOMA CRANIOPHARYNGIOMA TRANSITIONAL MENINGIOMA CARCINOMA, METASTATIC, NOS DIFFUSE NON-HODGKIN'S LYMPHOMA, LARGE CELL PILOCYTIC ASTROCYTOMA ANAPLASTIC ASTROCYTOMA OF BRAIN EPENDYMOMA NOS ANGIOMATOUS MENINGIOMA INFLAMMATORY DISORDER HEMATOMA Our Biobank Inventory Grade Grade I tumor (juvenile pilocytic astrocytoma) Grade II tumor (astrocytoma) Grade III tumor (anaplastic astrocytoma) Grade IV tumor (glioblastoma) Comments Benign, slow-growing tumor; usually associated with long-term survival; least likely to recur Increased hypercellularity; no mitosis; no vascular proliferation; no necrosis; can recur as a higher-grade tumor High rate of hypercellularity; high rate of mitosis; no vascular proliferation; no necrosis; high rate of tumor recurrence Very high rate of hypercellularity; very high rate of mitosis; presence of vascular proliferation; presence of necrosis WHO Grading System for Gliomas
